FDA extends the comment period on the GLP-1 compounding proposal to July 30

The U.S. Food and Drug Administration published a notice in the Federal Register on June 26, 2026 extending the public comment deadline on its proposal not to add semaglutide, tirzepatide or liraglutide to the list of bulk drug substances that outsourcing facilities may use in compounding, known as the 503B Bulks List ^[2]. Comments were due by 11:59 p.m. Eastern Time at the end of July 30, 2026 ^[2].

The agency had opened the question on May 1, 2026 with a 60-day comment period ^[2]. It then received a request for a 60-day extension, arguing that the original window did not allow enough time to develop "a meaningful or thoughtful response" and that more time would let interested parties address "complex clinical, public health, and legal issues" and "issues around patient safety and access to high-quality medications" ^[2].

The FDA granted half of what was asked. It extended the period by 30 days instead of 60, saying that length "appropriately balances allowing adequate time for interested persons to submit comments with avoiding significant delay of Agency action on these important issues" ^[2]. The agency encouraged commenters to address the clinical need standard set by the statute and the reasoning laid out in the May 1 notice ^[2]. Late comments would not be considered ^[2].

The filing appeared under Docket No. FDA-2018-N-3240 and was published at 91 FR 38719 ^[1]. Supporting material posted to that docket includes FDA evaluations of tirzepatide and liraglutide for 503B compounding ^[1]. The notice was signed by Grace R. Graham, deputy commissioner for policy, legislation and international affairs ^[2].

What the 503B list controls

Federal law separates two kinds of compounding. A traditional 503A pharmacy prepares a medication for one patient with a specific prescription, while a 503B outsourcing facility makes large batches without patient-specific prescriptions and ships them at scale ^[3]. That large-batch model is what made low-cost telehealth GLP-1 subscriptions possible, because a pharmacy filling one prescription at a time cannot supply tens of thousands of customers ^[3].

The FDA's proposal, if finalized, would keep semaglutide, tirzepatide and liraglutide off the clinical-need list that governs which bulk active ingredients outsourcing facilities may use ^[2][3]. Comments on the proposal "will inform FDA's final determination whether to include these substances on the 503B Bulks List," the agency wrote ^[2].

Why it matters for patients

Nothing about the legal status of compounded GLP-1 medicines changed on July 30. That date was the close of the comment window, not a shutdown date, and the proposal is not final ^[3]. No final determination has been announced, and no date for one has been published ^[3].

For people using compounded semaglutide or tirzepatide, the practical issue is timing and supply. If the FDA finalizes its proposal, 503B facilities would have to stop producing these three substances in bulk, and the supply feeding many compounded programs would narrow from the top ^[3]. How long that takes, and whether the agency changes course after reviewing comments, is not yet known.

Separately, the FDA has said compounders cannot sell what amounts to a copy of a commercially available drug in the same or similar strength, and it has cited marketing claims that a compounded product is the "same" as an FDA-approved drug as misleading ^[3]. Brand-name semaglutide is sold as Ozempic, Wegovy and Rybelsus; tirzepatide is sold as Mounjaro and Zepbound.

What happens next

May 1, 2026: FDA publishes its proposal with a 60-day comment period ^[2]. June 26, 2026: FDA extends the deadline by 30 days ^[2]. July 30, 2026: comment period closes at 11:59 p.m. Eastern ^[2]. After that, the agency reviews the record and decides whether to issue a final determination; the timing has not been disclosed ^[2][3]. Questions about the docket go to the FDA's compounding staff in the Center for Drug Evaluation and Research ^[2].